a public good project by the
Synthesis
Company
of California

© 2026

Danièle Ouellet | doi.page

0 works0 citations0 h-index

Danièle Ouellet

Johnson & Johnson (United States)(US)Springhouse(US)

Publications by Year

Research Areas

Melanoma and MAPK Pathways, Pharmacogenetics and Drug Metabolism, Statistical Methods in Clinical Trials, Computational Drug Discovery Methods, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

→ Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
→ Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma(2012)2,130 cited
→ Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
→ Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial(2012)929 cited
→ Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor(2012)473 cited
→ Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers(1998)175 cited

→ How Modeling and Simulation Have Enhanced Decision Making in New Drug Development(2005)

143 cited

Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.(1997)

→ Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).(2011)122 cited

→ Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities(2014)95 cited